Melatonin Peptide Complex

A melatonin peptide complex pairs exogenous melatonin with one or more sleep-related bioregulator peptides — most commonly delta sleep-inducing peptide (DSIP) and/or the synthetic pineal tetrapeptide Epitalon (Ala-Glu-Asp-Gly) — to act on the sleep-wake axis through complementary but distinct pathways.

Melatonin is an indoleamine hormone secreted by the pineal gland in response to darkness. It exerts its primary sleep-regulatory effects through two G protein-coupled receptors, MT1 and MT2. MT1 receptors are concentrated in the locus coeruleus and lateral hypothalamus and are linked to REM sleep regulation, while MT2 receptors are concentrated in the reticular thalamus and are associated with non-REM (NREM) sleep promotion. Both receptor subtypes are expressed in the suprachiasmatic nucleus (SCN), where melatonin dampens SCN neuronal firing to signal circadian night, thereby shifting the phase of endogenous biological rhythms. Research in knockout mouse models has demonstrated that loss of MT2 selectively reduces NREM sleep, while loss of MT1 selectively reduces REM sleep.

DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from venous blood of rabbits in sleep. In vitro studies using perifused rat pineal glands show that DSIP dose-dependently stimulates release of melatonin, serotonin, and 5-methoxytryptophol, through a pathway independent of classical noradrenergic or opioid systems. It also interacts with NMDA receptors and components of the MAPK cascade, though its receptor binding remains incompletely characterized after four decades of study.

Epitalon is proposed to act upstream by upregulating arylalkylamine N-acetyltransferase (AANAT) — the rate-limiting enzyme in melatonin biosynthesis — and the transcription factor pCREB within pinealocytes, thereby augmenting endogenous melatonin production rather than substituting for it. The rationale for combining these agents is that exogenous melatonin provides immediate circadian signaling while the peptide components modulate the capacity and rhythm of endogenous pineal output.

The evidence base is highly asymmetric: melatonin alone is supported by substantial controlled trial data, while the peptide components of such complexes have only sparse, small, or predominantly preclinical human evidence, and no clinical trial has evaluated the combination as a unit.

For melatonin, a 2013 meta-analysis of 19 randomized placebo-controlled trials (n = 1,683; PMID 23691095) found that melatonin reduced sleep-onset latency by a weighted mean of 7.06 minutes (95% CI 4.37–9.75, p < 0.001) and increased total sleep time by 8.25 minutes (95% CI 1.74–14.75, p = 0.013), with a small but statistically significant improvement in sleep quality (SMD = 0.22). A subsequent meta-analysis of 23 RCTs, published in 2021 (PMID 33417003), reported a clinically modest but significant improvement in Pittsburgh Sleep Quality Index scores (WMD −1.24 points, 95% CI −1.77 to −0.71), with the strongest subgroup effects in patients with metabolic disorders (WMD −2.74) and respiratory disease (WMD −2.20). Heterogeneity across studies was high (I² = 80.7%).

DSIP human data are limited to small, largely uncontrolled investigations. An open series of 10 intravenous DSIP injections in seven patients with severe insomnia (PMID 6391926) normalized sleep in six of seven, with daytime mood and performance also reportedly improved; follow-up at 3–7 months showed persistent benefit. A separate acute IV infusion study in six chronic insomniacs at 25 nmol/kg (PMID 7028502) demonstrated improved sleep duration, quality, and continuity, with a slight arousing effect in the first hour followed by normalizing sleep from the second hour onward; no daytime sedation was observed. No large, blinded, randomized controlled trial for DSIP exists.

For Epitalon, a human circadian study in 75 women found that 0.5 mg sublingual daily for 20 days increased melatonin excretion 1.6-fold and altered expression of circadian clock genes (PMID 22585246). A separate clinical trial in 162 patients with retinitis pigmentosa reported visual and circadian outcomes, but no dedicated insomnia or polysomnography data were collected. The bulk of Epitalon research originates from a single group at the St. Petersburg Institute of Bioregulation and Gerontology and has not been independently replicated at scale.

No published clinical trial has examined a formulated melatonin-plus-peptide complex as a combined intervention in humans.

Typical dosage: 3-10 mg (before bed).

Melatonin component: The range most consistently studied in randomized trials is 0.5 mg to 5 mg taken orally 30–60 minutes before the target bedtime. A 2013 meta-analysis noted that higher doses within this range produced larger effects on sleep-onset latency. Physiological endogenous nocturnal melatonin levels are typically in the 0.1–0.3 mg equivalent range; doses of 0.5–1 mg are considered near-physiological and are preferred by some clinicians to minimize receptor desensitization. Doses above 5 mg appear to offer no additional sleep benefit in most trials. Prolonged-release formulations (e.g., 2 mg) are used in some markets specifically for sleep-maintenance complaints in adults over 55.

DSIP component: All human trial data involved intravenous or parenteral administration; no validated oral bioavailability data exist. Published human studies used approximately 25 nmol/kg intravenously or a series of 10 injections without a standardized per-dose weight. In research and compounding contexts, subcutaneous doses of 100–500 mcg have been reported anecdotally, but no pharmacokinetic study has established systemic exposure or efficacy via this route. DSIP's in vitro half-life is approximately 15 minutes due to aminopeptidase degradation, raising questions about oral utility.

Epitalon component: The only published human dosing data involve 0.5 mg sublingually once daily for 20 days (circadian study, n = 75) and 5 mcg parabulbar injection over 10 consecutive days (retinal disease trial, n = 162). No dose-response data in humans for sleep outcomes are available.

This information is provided for educational and reference purposes only and does not constitute medical advice. These compounds vary widely in regulatory status across jurisdictions; consultation with a qualified physician is necessary before any therapeutic use.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Within the broader category of melatonin peptide complexes, several pairing rationales appear in the research and practitioner literature, though most combination evidence is anecdotal.

• Melatonin + DSIP: The most commonly discussed combination. The rationale is mechanistic complementarity — melatonin synchronizes circadian phase via SCN MT1/MT2 activation while DSIP is proposed to enhance delta-wave architecture independent of circadian signaling. No published trial has examined this combination in humans; evidence is anecdotal.

• Melatonin + Epitalon: Some practitioners combine low-dose melatonin for immediate circadian support with Epitalon to address age-related decline in endogenous pineal melatonin production. The concern raised in the literature is that long-term exogenous melatonin may suppress endogenous synthesis via negative feedback, making the addition of a synthesis-upregulating peptide theoretically attractive. This remains speculative and anecdotal.

• Melatonin + L-theanine or magnesium glycinate: Commercially available sleep complexes frequently pair melatonin with L-theanine (a glutamate receptor modulator with some human RCT data for relaxation) and magnesium (which supports GABA-ergic signaling). Small randomized trials for L-theanine on sleep quality exist but are not specific to peptide-containing formulas.

All multi-component combination protocols should be considered anecdotal or at best expert opinion in the absence of clinical trial data for the combinations themselves.

Melatonin Peptide Complex is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Possible morning grogginess

Melatonin: A systematic review and meta-analysis of 79 RCTs (n = 3,861; PMC10109390) examining doses of 10 mg or higher found no significant increase in serious adverse events (rate ratio 0.88) or treatment withdrawals due to side effects, but did find an increased risk of drowsiness, headache, and dizziness (pooled rate ratio 1.40, p < 0.001). These effects were described as minor, short-lived, and easily managed. At therapeutic doses of 0.5–5 mg, adverse events are uncommon. Clinically important interactions include: fluvoxamine, which inhibits CYP1A2 and can markedly increase melatonin plasma levels; anticoagulants such as warfarin, where additive antiplatelet effects may increase bleeding risk; and antihypertensive agents, where melatonin may alter cardiovascular parameters at higher doses. Safety data in pregnancy are insufficient; routine use during pregnancy or breastfeeding is not recommended. Use in pre-adolescent children and patients with epilepsy or asthma warrants caution. Long-term safety at doses exceeding 5–6 mg daily has not been established in rigorous prospective studies.

DSIP: No significant adverse effects were reported in the small human trials available. Transient headache, nausea, and vertigo have been noted in some participants. One study reported a slight arousing effect within the first hour of IV infusion. Standardized long-term toxicity studies do not exist, and the compound is not approved by the FDA or EMA for any therapeutic indication. Safety data are insufficient to characterize risk with repeated or extended use.

Epitalon: A 2025 comprehensive review (PMC11943447) noted that no nephrotoxicity or genotoxic effects were observed in preclinical models and no adverse events were reported in the 162-patient clinical trial, but explicitly stated that information on short- and long-term toxicity, carcinogenic potential, and drug interactions is missing. The authors recommended these studies before designation as an active pharmaceutical ingredient.